BioNexus Gene Lab Corp Balance Sheet
BGLC|7 years of annual SEC 10-K data (FY2019-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$9M
FY2025
Cash
$2M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$9M
FY2025
BioNexus Gene Lab Corp had $9M in total assets and $9M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -34.6% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | $2.9M | - | - | $2.1M | $2.8M | $859.1K |
| Accounts Receivable | $505.9K | $1.4M | $799.7K | $2.9M | $3.4M | - | - |
| Inventory | $676.7K | $1.4M | $1.1M | $977.8K | $1.5M | $1.2M | $7.6K |
| Current Assets | $5.4M | $7.4M | $8.0M | $6.0M | $7.1M | $8.0M | $882.6K |
| PP&E (Net) | $1.6M | $1.5M | $1.5M | $1.5M | $1.6M | $1.8M | $312.9K |
| Total Assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M | $1.2M |
| Current Liabilities | $521.0K | $2.0M | $1.6M | $2.0M | $2.3M | $3.4M | $51.6K |
| Shareholders' Equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M |